KLRA
Kailera Therapeutics, Inc. Common StockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$2.74B
P/E Ratio
—
EPS
$-1.26
Beta
—
52W High
$28.23
52W Low
$16.00
50-Day MA
$23.01
200-Day MA
$23.01
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Kailera Therapeutics, Inc. Common Stock
Kailera Therapeutics, Inc. is a biotechnology company focused on developing innovative gene therapies for rare genetic diseases, leveraging advanced technologies to address unmet medical needs. The company's proprietary platform is designed to enhance the precision and effectiveness of therapeutic interventions, targeting various genetic disorders. By collaborating with leading research institutions and leveraging a robust intellectual property portfolio, Kailera aims to bring transformative treatments to patients and position itself as a leader in the gene therapy market. As it advances its product pipeline, Kailera is committed to delivering sustainable value to its investors and stakeholders.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-158.03M |
| Operating Margin | 0.00% |
| Return on Equity | -36.90% |
| Return on Assets | -22.70% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-18713.67 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $129.54M |
| Float | 8,660 |
| % Insiders | 0.00% |
| % Institutions | 37.70% |
More HEALTHCARE Stocks
Data last updated: 5/25/2026